NeXT Level
Biomarkers Symposium

NeXT Level Biomarkers Symposium

June 22, 2021
8:00 AM – 12:00 PM Pacific

The 2021 Personalis NeXT Level Biomarkers Symposium will showcase the latest research from Personalis’ ImmunoID NeXT Platform™ and highlight key applications of the most comprehensive immunogenomics solution for translational research. Please join us for a presentation from the Parker Institute for Cancer Immunotherapy and see how the ImmunoID NeXT Platform is impacting real world biomarker discovery. The Personalis Research and Development team will also be presenting the latest insights and applications from our internal research and will highlight the technical capabilities of ImmunoID NeXT.

Agenda

The 2021 NeXT Level Biomarkers Symposium will cover novel research put forth by the Personalis R&D team as well as a client presentation from our partners at the Parker Institute for Cancer Immunotherapy. Topics included are:

  • HLA LOH and HLA typing using our Deletion of Allele-Specific HLAs (DASH) technology
  • Neoantigen prediction capabilities using our Systematic HLA Epitope Ranking Pan Algorithm (SHERPA)
  • NeXT Dx and companion diagnostics development from NGS data
  • Case study on leveraging the data from Personalis’ ImmunoID NeXT Platform from the Parker Institute for Cancer Immunotherapy
TopicSpeakerTime (Pacific)
Welcome / Opening AddressErin Newburn8:00 – 8:05 AM
Biomarker Discovery with ImmunoID NeXT PlatformErin Newburn8:05 – 8:25 AM
Networking SessionSpeakers & Attendees8:25 – 8:55 AM
Exploring HLA LOH With the DASH (Deletion of Allele-Specific HLAs) AlgorithmRachel Pyke8:55 – 9:20 AM
Neoantigen Binding Prediction and Biomarker Discovery with SHERPASean Boyle9:20 – 9:45 AM
Composite Biomarkers and our Neoantigen Presentation Score (NEOPS)Charles Abbott9:45 – 10:10 AM
Break10:10 – 10:25 AM
Parker Institute Case Study: The PRINCE TrialTheresa Lavallee
Lee McDaniel
10:25 – 10:55 AM
NeXT Liquid Biopsy Overview and Review of AACR DataSean Boyle
Dan Norton
10:55 – 11:20 AM
NeXT Dx and Companion Diagnostics (CDx) with PersonalisTwinkal Marfatia
Dawn McHugh
11:20 – 11:45 AM
Final Summary & ClosingErin Newburn11:45 – 12:00 PM

Guest Speaker

Theresa Lavallee, PhD

Vice President, Translation Medicine and Regulatory Affairs
Parker Institute for Cancer Immunotherapy

Theresa LaVallee has over 25 years of research and industry experience with a broad knowledge in the discovery and development of drug candidates. Theresa is Vice President, Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy and previously served as Senior Vice President, Celldex Therapeutics and Kolltan Pharmaceuticals. She also was Senior Director Translational Medicine at MedImmune and EntreMed. In these roles, she has advanced drugs in oncology, immunology and inflammatory diseases from discovery through late stage development. Theresa has a depth of expertise in Translational Medicine enabling science driven development decisions and implementing effective use of biomarker assays in clinical studies. She is author or co-author of more than 50 publications and abstracts with a focus on Translational Medicine approaches in clinical development. She received her Ph.D. degree from University of California, Los Angeles and her B.A. degree from the University of California, Santa Barbara.

Personalis Speakers

Erin Newburn, MS, PhD

Director, Field Applications Science
Personalis, Inc. 

Sean Boyle, PhD

Senior Director, Bioinformatics Applications
Personalis, Inc.

Charles Abbott

Charles Abbott, PhD

Manager Bioinformatics Science
Personalis, Inc.

Rachel Pyke, PhD

Manager, Bioinformatics Applications
Personalis, Inc. 

Dan Norton, MBA

Senior Product Manager
Personalis, Inc. 

Dawn McHugh

Sr. Director, Strategic Business Development
Personalis, Inc. 

Twinkal Marfatia

Twinkal Marfatia, PhD

Sr. Product Manager – Clinical Products
Personalis, Inc. 

Lee McDaniel

Lee McDaniel, PhD

Sr. Bioinformatics Scientist
Personalis, Inc. 

With ImmunoID NeXT, oncology researchers can comprehensively analyze both a tumor and its microenvironment from a single tumor sample. It enables customers to maximize the data generated from each sample while also decreasing the complexity of data interpretation by eliminating the need to integrate multiple assay technologies and reporting formats from several sources.

Specifically built for immuno-/precision oncology, the NeXT Platform is used to investigate key areas of tumor biology; from elucidating mechanisms of tumor escape and detecting neoantigens, to identifying novel gene expression signatures and characterizing the immune repertoire. With these extensive capabilities, ImmunoID NeXT effectively consolidates multiple biomarker assays into one.

The unique design of the assay and analytical algorithms enables the delivery of critical tumor- and immune-related information including, but not limited to:

  • T-cell receptor (TCR) alpha & beta repertoire
  • Neoantigen detection and neoantigen load
  • Tumor mutational burden (TMB)
  • Microsatellite instability (MSI) characterization
  • Human leukocyte antigens (HLA) typing, HLA and beta-2 microglobulin (B2M) somatic mutations, and HLA loss of heterozygosity (LOH)
  • Tumor escape and resistance mechanisms
  • Oncoviral detection